Literature DB >> 19004042

Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996-2004.

Michael M Ward1.   

Abstract

OBJECTIVE: To determine if the incidence of endstage renal disease (ESRD) due to lupus nephritis has decreased from 1996 to 2004.
METHODS: Patients age 15 years or older with incident ESRD due to lupus nephritis in 1996-2004 and living in one of the 50 United States or the District of Columbia were identified using the US Renal Data System, a national population-based registry of all patients receiving renal replacement therapy for ESRD. Incidence rates were computed for each calendar year, using population estimates of the US census as denominators.
RESULTS: Over the 9-year study period, 9199 new cases of ESRD due to lupus nephritis were observed. Incidence rates, adjusted to the age, sex, and race composition of the US population in 2000, were 4.4 per million in 1996 and 4.9 per million in 2004. Compared to the pooled incidence rate in 1996-1998, the relative risk of ESRD due to lupus nephritis in 1999-2000 was 0.99 (95% CI 0.93-1.06), in 2001-2002 was 0.99 (95% CI 0.92-1.06), and in 2003-2004 was 0.96 (95% CI 0.89-1.02). Findings were similar in analyses stratified by sex, age group, race, and socioeconomic status.
CONCLUSION: There was no decrease in the incidence of ESRD due to lupus nephritis between 1996 and 2004. This may reflect the limits of effectiveness of current treatments, or limitations in access, use, or adherence to treatment.

Entities:  

Mesh:

Year:  2009        PMID: 19004042      PMCID: PMC2679678          DOI: 10.3899/jrheum.080625

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  11 in total

1.  Association between hospital process performance and outcomes among patients with acute coronary syndromes.

Authors:  Eric D Peterson; Matthew T Roe; Jyotsna Mulgund; Elizabeth R DeLong; Barbara L Lytle; Ralph G Brindis; Sidney C Smith; Charles V Pollack; L Kristin Newby; Robert A Harrington; W Brian Gibler; E Magnus Ohman
Journal:  JAMA       Date:  2006-04-26       Impact factor: 56.272

2.  Care in U.S. hospitals--the Hospital Quality Alliance program.

Authors:  Ashish K Jha; Zhonghe Li; E John Orav; Arnold M Epstein
Journal:  N Engl J Med       Date:  2005-07-21       Impact factor: 91.245

Review 3.  Applying clinical epidemiological methods to health equity: the equity effectiveness loop.

Authors:  Peter Tugwell; Don de Savigny; Gillian Hawker; Vivian Robinson
Journal:  BMJ       Date:  2006-02-11

4.  Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the united states. HCSUS Consortium. HIV Cost and Services Utilization.

Authors:  W E Cunningham; L E Markson; R M Andersen; S H Crystal; J A Fleishman; C Golin; A Gifford; H H Liu; T T Nakazono; S Morton; S A Bozzette; M F Shapiro; N S Wenger
Journal:  J Acquir Immune Defic Syndr       Date:  2000-10-01       Impact factor: 3.731

5.  Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure.

Authors:  Mikkel Faurschou; Henrik Starklint; Poul Halberg; Søren Jacobsen
Journal:  J Rheumatol       Date:  2006-08       Impact factor: 4.666

6.  Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995.

Authors:  M M Ward
Journal:  Arch Intern Med       Date:  2000-11-13

7.  Factors associated with refractory renal disease in patients with systemic lupus erythematosus: the role of patient nonadherence.

Authors:  I N Bruce; D D Gladman; M B Urowitz
Journal:  Arthritis Care Res       Date:  2000-12

8.  Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment.

Authors:  C Fiehn; Y Hajjar; K Mueller; R Waldherr; A D Ho; K Andrassy
Journal:  Ann Rheum Dis       Date:  2003-05       Impact factor: 19.103

9.  Factors associated with vaccination of medicare beneficiaries in five U.S. communities: Results from the racial and ethnic adult disparities in immunization initiative survey, 2003.

Authors:  Carla A Winston; Pascale M Wortley; Karen A Lees
Journal:  J Am Geriatr Soc       Date:  2006-02       Impact factor: 5.562

10.  Socioeconomic status and the incidence of ESRD.

Authors:  Michael M Ward
Journal:  Am J Kidney Dis       Date:  2008-02-07       Impact factor: 8.860

View more
  42 in total

1.  Urinary vascular cell adhesion molecule, but not neutrophil gelatinase-associated lipocalin, is associated with lupus nephritis.

Authors:  Adnan N Kiani; Tianfu Wu; Hong Fang; Xin J Zhou; Chul W Ahn; Laurence S Magder; Chandra Mohan; Michelle Petri
Journal:  J Rheumatol       Date:  2012-04-15       Impact factor: 4.666

2.  The persistent challenge of lupus nephritis.

Authors:  Guido Valesini; Fabrizio Conti
Journal:  Clin Rev Allergy Immunol       Date:  2011-06       Impact factor: 8.667

3.  Cross-species transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritis.

Authors:  Celine C Berthier; Ramalingam Bethunaickan; Tania Gonzalez-Rivera; Viji Nair; Meera Ramanujam; Weijia Zhang; Erwin P Bottinger; Stephan Segerer; Maja Lindenmeyer; Clemens D Cohen; Anne Davidson; Matthias Kretzler
Journal:  J Immunol       Date:  2012-06-20       Impact factor: 5.422

4.  American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis.

Authors:  Bevra H Hahn; Maureen A McMahon; Alan Wilkinson; W Dean Wallace; David I Daikh; John D Fitzgerald; George A Karpouzas; Joan T Merrill; Daniel J Wallace; Jinoos Yazdany; Rosalind Ramsey-Goldman; Karandeep Singh; Mazdak Khalighi; Soo-In Choi; Maneesh Gogia; Suzanne Kafaja; Mohammad Kamgar; Christine Lau; William J Martin; Sefali Parikh; Justin Peng; Anjay Rastogi; Weiling Chen; Jennifer M Grossman
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-06       Impact factor: 4.794

5.  Quality of care for incident lupus nephritis among Medicaid beneficiaries in the United States.

Authors:  Jinoos Yazdany; Candace H Feldman; Jun Liu; Michael M Ward; Michael A Fischer; Karen H Costenbader
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-04       Impact factor: 4.794

6.  Connective tissue diseases: Lupus nephritis-winning a few battles but not the war.

Authors:  George K Bertsias; Dimitrios T Boumpas
Journal:  Nat Rev Rheumatol       Date:  2011-06-21       Impact factor: 20.543

7.  Identification of stage-specific genes associated with lupus nephritis and response to remission induction in (NZB × NZW)F1 and NZM2410 mice.

Authors:  Ramalingam Bethunaickan; Celine C Berthier; Weijia Zhang; Ridvan Eksi; Hong-Dong Li; Yuanfang Guan; Matthias Kretzler; Anne Davidson
Journal:  Arthritis Rheumatol       Date:  2014-08       Impact factor: 10.995

8.  The first year results of mizoribine/tacrolimus-based multitarget treatment for consecutive patients with lupus nephritis.

Authors:  Hidetoshi Kagawa; Tsutomu Hiromasa; Ryutaro Yamanaka; Reika Hayashi; Yoko Tsunashima; Tatsuyuki Inoue; Ken-Ei Sada
Journal:  Clin Exp Nephrol       Date:  2018-06-09       Impact factor: 2.801

9.  Longitudinal assessment of monocyte chemoattractant protein-1 in lupus nephritis as a biomarker of disease activity.

Authors:  Ranjan Gupta; Akhilesh Yadav; Amita Aggarwal
Journal:  Clin Rheumatol       Date:  2016-09-13       Impact factor: 2.980

Review 10.  Autoimmunity, end organ damage, and the origin of autoantibodies and autoreactive T cells in systemic lupus erythematosus.

Authors:  Janet E Lewis; Shu Man Fu; Felicia Gaskin
Journal:  Discov Med       Date:  2013-02       Impact factor: 2.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.